Erythropoietin as candidate for supportive treatment of severe COVID-19

In light of the present therapeutic situation in COVID-19, any measure to improve course and outcome of seriously affected individuals is of utmost importance. We recap here evidence that supports the use of human recombinant erythropoietin (EPO) for ameliorating course and outcome of seriously ill...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehrenreich, Hannelore, Weissenborn, Karin, Begemann, Martin, Busch, Markus, Vieta, Eduard, Miskowiak, Kamilla W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297268/
https://www.ncbi.nlm.nih.gov/pubmed/32546125
http://dx.doi.org/10.1186/s10020-020-00186-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297268/
https://www.ncbi.nlm.nih.gov/pubmed/32546125
http://dx.doi.org/10.1186/s10020-020-00186-y

Ejemplares similares